Our Board

jonathan-kowalski

Jonathan Kowalski

Chief Practice Officer: Value Demonstration and Executive Vice President, Head of BresMed US

Jonathan is responsible for accelerating the expansion of BresMed’s presence and scope of services in the US to help clients succeed in early pipeline value strategy and evidence planning, health technology assessment, new product payer engagement and launch excellence, and post-approval product differentiation. Building on BresMed’s global capabilities in early-phase and pre-HTA evidence generation planning, qualitative research, clinical evidence review and value communications, Jonathan also leads the Value Demonstration practice.

Jonathan joined BresMed in September 2020 following more than 20 years at Allergan (Irvine, California) where he held a number of US and Global HEOR, market access and health-policy leadership roles: VP and Head, US Health Outcomes and Value; VP, US HEOR and Global HEOR Initiatives. Jonathan also held increasing roles of responsibility in leading global HEOR and strategy for key franchises, including ophthalmology, urology, medical dermatology and facial aesthetics.

What Jonathan says about BresMed: “Before joining the BresMed team, I was a client for more than a decade and relied upon BresMed’s excellence in research, insightful strategic counsel and exceptional client service. Now that I have joined BresMed, I am keen to ensure that as many clients as possible enjoy the same high level of technical support and service, ultimately enabling them to achieve successful access for their technologies and improved health for the patients who rely on them.”

Curriculum vitae

Employment history

2017–2020   Vice President and Head, US Health Outcomes and Value   Allergan, plc.

2015–2017   Vice President, US Health Economics and Outcomes Research and Global HEOR Initiatives   Allergan, plc.

2014–2015   Vice President and Head, US Health Outcomes   Allergan, plc.

2010–2014   Senior Director and Global Therapy Area Head, Ophthalmology   Allergan, Inc.

2007–2010   Director, Global Lead for Retina, Medical Dermatology, Facial Aesthetics, and Urology   Allergan, Inc.

2005–2007   Senior Manager, Global Lead for Retina, Medical Dermatology, and Facial Aesthetics   Allergan, Inc.

2002–2005   Manager, Global Lead for Medical Dermatology and Facial Aesthetics   Allergan, Inc.

2000–2002   Manager, US Lead for Ophthalmic Surgical and Medical Dermatology   Allergan, Inc.

1999–2000   Manager, Outcomes Research and US Lead for Urology   ALZA, Inc.

1997–1999   Post-doctoral Research Fellow   Roche Global Pharmacoeconomic Research

 

Research interests

Current research areas include:

  • Cost-effectiveness and budget impact modelling
  • Clinical outcomes assessment development and validation
  • Claims database and electronic health record analysis
  • Design and implementation of patient-focused quality improvement programs
  • Early commercialization and value demonstration planning

 

Therapeutic areas of expertise

Ophthalmology, Neurology, Psychiatry, Urology, Cardiology, Medical Dermatology, Medical Aesthetics, Immunology, Gastrointestinal, Infectious Disease, Women’s Health, and Oncology.

 

Chairs and Memberships

Present:

  • Academy of Managed Care Pharmacy
  • International Society for Pharmacoeconomics and Outcomes Research

Previous

  • International Society for Quality of Life Research
  • Association for Research and Vision in Ophthalmology
  • American Society of Health-System Pharmacists

 

Referee/Reviewer roles

  • Archives of Dermatology
  • Canadian Medical Association Journal
  • Quality of Life Research

Publications

Other publications

Book Chapter

Koo JYM, Kowalski JW, Lebwohl M, Kozma CM, Menter A. Chapter 3. The Koo-Menter Psoriasis Instrument for identifying candidate patients for systemic therapy.  In: Mild-to-Moderate Psoriasis.  Eds.  Koo JYM, Lebwohl M, Lee CS.  Informa Healthcare 2006.

 

Peer-Reviewed Manuscripts

Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia 2019 Apr;39(4):465-476.

Sussman D, Yehoshua, Kowalski JW, Lee J, Kish S, Chaudhari S, Murray B. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis. Int J Clin Pract 2017;71:e12824

Wallick C, Hansen R, Campbell J, Kiss S, Kowalski JW, Sullivan S. Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina 2015;46:744-751

Yaworsky A, Daniels S, Tully S, Beddingfield F, Kowalski JW, Fitzgerald K, Somogyi C, Burgess SM. The Impact of Upper Facial Lines and Psychological Impact of Crow’s Feet Lines: Content Validation of the Facial Line Outcomes (FLO-11) Questionnaire. J Cosmet Dermatol 2014;13(4):297-306

Dayan S, Coleman W, Dover JS, De Boulle K, Daniels S , Kowalski JW, Lei X, Lee E. Effects of OnabotulinumtoxinA Treatment for Crow’s Feet Lines on Patient-Reported Outcomes. Dermatol Surg 2015;41:S67-S74

Rentz AM, Kowalski JW, Walt JG, Hays RD, Brazier JE, Yu R, Lee P, Bressler N, Revicki DA. Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.  JAMA Ophthalmol 2014;132(3):310-318

Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema Clinical Ophthalmology 2014;8:1611–1621

Kiss S, Liu Y, Brown J, Holekamp NM, Almony A, Campbell J, Kowalski JW. Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmic Surg Lasers Imaging Retina 2014;45(4):285-91

Holekamp NM, , Liu Y, Yeh W-S, Chia Y, Kiss S, Almony A, Kowalski JW. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmology 2014;157(4):825–833.

Campbell JK, Schwartz GF, LaBounty B, Kowalski JW, Patel VD. Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clinical ophthalmology 2014;8:927-935

Campbell JK, Schwartz GF, LaBounty B, Kowalski JW, Patel VD.  Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Current Medical Research and Opinion 2013;29(9):1201-1209

Wong WB, Patel VD, Kowalski JW, Schwartz GF. An adherence-based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. Current Medical Research and Opinion 2013;29(9)2013;29(9):1191-1200

Patrick DL, Khalaf KM, Dmochowski R, Kowalski JW, Globe DR. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clinical Therapeutics 2013;35(6):836-485

Naik RK, Rentz AM, Foster CS, Lightman S, Belfort R, Lowder CY, Whitcup SM, Kowalski JW, Revicki DA. Normative comparison of patient-reported outcomes in patients with noninfectious intermediate or posterior uveitis. JAMA Ophthalmol 2013; 131(2):219-225

Lightman S, Belfort R, Naik RK, Lowder CY, Foster CS, Rentz AM, Cui H, Whitcup SM, Kowalski JW, Revicki DA. Vision related functioning outcomes of dexamethasone intravitreal implant for the treatment of patients with noninfectious intermediate or posterior uvetitis: Results of a randomized clinical trial. Investigative Ophthalmology & Visual Science 2013;54:4864-4870

Naik RK, Gries KS, Rentz AM, Kowalski JW, Revicki DA. Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis. Quality of Life Research 2013; 22(10):2801-2808

Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, et al. The global prevalence and major risk factors of diabetic retinopathy and vision-threatening retinopathy in persons with diabetes. Diabetes Care 2012; 35(3):556-64.

Kowalski JW, Rentz AM, Walt JG, Lloyd A, Lee J, Young TA, Chen WH, Bressler NM, Lee P, Brazier JE, Hays RD, Revicki DA. Rasch analysis in the development of a simplified version of the national eye institute visual-function questionnaire-25 for utility estimation. Qual Life Res 2012;21:323-334.

Yeh W-S, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treatment with dexamethasone intravitreal implant. Ophthalmology 2012; 119(6):1190-1198

Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: A 36-week double-blind, placebo-controlled, randomized, dose-ranging trial. European Urology 2012; 62(1):148-57

Kowalski JW, Hayward E, Almond CM, Trueman D. Economic evaluation of the treatment of patients with macular edema secondary to retinal vein occlusion with a biodegradable dexamethasone intravitreal implant in Italy. PharmacoEconomics – Italian Research Articles 2012; 14 (1): 29-38

Fekrat S, Shea AM, Hammill BG, Nguyen H, Kowalski JW, Schulman KA, Curtis LH. Resource use and costs of branch and central vein occlusion in the elderly.  Current Medical Research & Opinion 2010;26(1):223-230.

Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, Sullivan SD. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res January 2010 Apr;19(3):323-31.

McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117(6):1113-1123.

Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117(6):1094-1101.

Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY. The prevalence of retinal vein occlusion:  pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117(2):313-319.

Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 2010;76:835-840.

Fowler C, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Kowalski JW, Zhou J. Botulinum toxin A (BOTOX®) demonstrates dose-dependent improvements in health-related quality-of-life measures in idiopathic overactive bladder. Journal of Urology 2009;181(4):558-558.

Bearelly S, Mruthyunjaya P, Tzeng JP, Suner IJ, Shea AM, Lee JT, Kowalski JW, Curtis LH, Schulman KA, Lee PP. Identification of patients with diabetic macular edema from claims data: a validation study.  Arch Ophthalmol 2008;126(7):986-989.

Shea AM, Curtis LH, Hammill BG, Kowalski JW, Ravelo A, Lee PP, Sloan FA, Schulman KA. Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008;126(12):1748-1754.

Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids:  a double-blind, randomized, placebo-controlled study. Dermatol Surg 2007;33(1):S2-9.

Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis:  a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007;56(4):604-611.

Stotland MA, Kowalski JW, Ray BB.  Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytids: results from a prospective open-label study. Plastic and Reconstructive Surgery 2007;120(5):1386-1393.

Hamm H, Naumann MK, Kowalski JW, Kütt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006; 212(4):343-353.

Solish N, Benohanian A, Kowalski JW. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 2005;31(4):405-413.

Strutton DR, Kowalski JW, Glaser DA, Stang PE.  US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004;51(2):241-248.

Cox SE, Finn JC, Stetler L, Mackowiak J, Kowalski, JW.  Development of the facial lines treatment satisfaction questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol Surg 2003;29(5):444-449.

Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE.  Gabapentin absorption: effect of mixing foods of varying macronutrient composition. Ann Pharmacother 1998;32:405-409.

 

Scientific Congresses: Abstracts, Posters and Podium Presentations

Pavlovic J,  Yu JS,  Silbertsein SD,  Reed ML,  Kawahara SH,  Cowan RP,  Dabbous F,  Campbell K,  Shewale AR,  Pulicharam R,  Kowalski JW,  Viswanathan HN,  Lipton RB. Development of a claims-based algorithm for use in patients with migraine to identify potentially undiagnosed chronic migraine patients. [Poster]. Annual Meeting of the American Academy of Neurology (AAN), 21-27 April 2018, Los Angeles, California.

Campbell J, Cole AL, Almony A, Ingraham H, Holekamp NM, Marks S, Chandwani H, Kowalski JW, Kiss S. Real-world vision outcomes in DME treated with anti-VEGF injections – An analysis of EMR data from a large health system. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 4-8 May 2014, Orlando, Florida.

Wallick CJ, Hansen RN, Campbell J, Kowalski JW, Kiss S, Sullivan SD. Increased health care utilization among patients with diabetic macular edema compared with diabetic patients without edema. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 4-8 May 2014, Orlando, Florida.

Kowalski JW, Campbell J, Schwartz GF, LaBounty B. Patient adherence and persistence with topical bimatoprost 0.01% and bimatoprost 0.03%: an analysis of latanoprost switchers. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 4-8 May 2014, Orlando, Florida.

Hayward E, Almond C, Trueman D, Yeh WS, Kowalski JW. The cost-effectiveness of Ozurdex® (dexamethasone intravitreal implant in applicator) compared with observation for the treatment of macular oedema following central and branch retinal vein occlusion. [Poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. 5-8 November 2011, Madrid, Spain.

Slater D, Yeh WS, Chia YF, Kowalski JW. Real-world utilization of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in common retinal diseases. [Poster].  Academy of Managed Care Pharmacy 2011 Educational Conference, 19-21 Oct 2011, Atlanta, Georgia.

Kowalski JW, Yeh WS, O’Leary B, Ackerman S, Adena M. Cost-effectiveness of a dexamethasone implant for the treatment of macular edema following retinal vein occlusion:  an Analysis based on the GENEVA studies. [Poster].   International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, 21-25 May 2011, Baltimore, Maryland.

Lin V, Yeh WS, Kowalski JW. Economic evaluations for screenings and treatments of diabetic retinopathy and diabetic macular edema: A systematic review. [Poster].  International Society for Pharmacoeconomics and Outcomes Research. 16th Annual International Meeting, 21-25 May 2011, Baltimore, Maryland.

Naik RK, Lowder CY, Lightman S, Rentz AM, Kowalski JW, Foster CS, Belfort R, Revicki D, Whitcup SM. Normative comparison of patient-reported outcomes in noninfectious intermediate or posterior uveitis.  [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 1-5 May 2011, Fort Lauderdale, Florida.

Yau J, Kawasaki R, Rogers S, Wong T, Kowalski JW, Lamoureux E. Global prevalence of vision-threatening diabetic retinopathy: pooled data from population studies from the United States, Australia, Europe and Asia. [Podium]. Association for Research in Vision and Ophthalmology (Asia-ARVO), 20-22 January 2011, Singapore.

Revicki DA, Rentz AM, Kowalski JW, Chen W-H. Assessment of unidimensionality for the visual function questionnaire-utility index (VFQ-UI) items in patients with central vision loss. [Poster]. International Society for Quality of Life (ISOQOL) Research Conference. 27-30 October 2010, London, England.

Haller JA, Belfort R, Heier J, Bandello F, Loewenstein A, Yoon YH, Whitcup SM, Liao L, Kowalski JW, Yeh WS. Benefits of early treatment with dexamethasone intravitreal implant in patients with macular edema due to BRVO or CRVO. [Poster]. American Academy of Ophthalmology Annual Meeting, 16-19 October 2010, Chicago, Illinois.

Faber D, Gupta S, Boyer D, Patel S, Gries K, Kowalski JW, Liu C, Lou J, Li X, Whitcup S. Visual functioning improvement with OZURDEX™ treatment in vitrectomized subjects with diabetic macular edema. [Podium]. American Society of Retina Specialists, 28 Aug – 1 Sept 2010, Vancouver, BC, Canada.

Campbell J, Velard M, Denys P, Chartier-Kastier E, Kowalski JW, Sullivan S. Cost-effectiveness and financial impact of botulinum toxin type A treatment for urinary incontinence due to neurogenic detrusor overactivity in spinal cord injury patients within the French healthcare system. [Poster]. International Continence Society and the International Urogynecological Association Meeting, 23-27 August 2010, Toronto, Canada.

Kowalski JW, Gelhorn H, Naik R, Rentz A, Cui H, Lowder C, Belfort R, Foster S, Lightman S, Whitcup SM. Efficacy of dexamethasone intravitreal implant for the treatment of uveitis based on patient-reported vision function outcome measures. [Poster]. World Ophthalmology Congress, 5-9 June 2010; Berlin, Germany.

Kowalski JW, Rentz A, Revicki D, Bandello F, Gilles M, Yoon Y, Liu C, Whitcup S. Effect of dexamethasone intravitreal implant on patient-reported visual functioning for the treatment of macular edema following retinal vein occlusion. [Podium]. World Ophthalmology Congress, 5-9 June 2010, Berlin, Germany.

Rentz A, Kowalski JW, Revicki D, Lowenstein A, Whitcup SM. Normative comparison of generic- and vision-targeted health-related quality of life (HRQL) outcomes in patients with vision loss due to macular edema following retinal vein occlusion. [Podium]. World Ophthalmology Congress, 5-9 June 2010, Berlin, Germany.

Kowalski JW, Bayliss M, Patel V, Patrick D, Fitzgerald K. Content validity of the I-QOL among patients with incontinence due to idiopathic overactive bladder (OAB). [Poster]. American Urological Association, 29 May – 3 June 2010, San Francisco, California.

Naik R, Gelhorn H, Kowalski JW, Cui H, Revicki D, Lowder C, Belfort R, Foster S, Whitcup SM. Efficacy of dexamethasone intravitreal implant for the treatment of uveitis based on patient-reported vision function outcome measures. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 2-6 May 2010, Fort Lauderdale, Florida.

Gries KS, Patrick DL, Kowalski JW, Sullivan SD. Validity and reliability of the visual function questionnaire utility index in individuals with age-related macular degeneration. [Poster].  International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, 15-19 May 2010, Atlanta, Georgia.

Yeung K, Robinson M, Kowalski JW.  The impact of geographic atrophy on managed care organizations. [Poster].  Academy of Managed Care Pharmacy, 7-9 Oct 2009, San Antonio, Texas.

Beddingfield F, Tully S, Kowalski JW, Scott J, Tateishi S, Burgess S. Content validation of the facial lines outcomes Questionnaire (FLO-11 v2.0) and the self-perception of age measure (SPA measure v3.0) in subjects with hyperfunctional lines of the upper face. [Poster]. American Society for Dermatologic Surgery, 1-4 Oct 2009, Phoenix, Arizona.

Brubaker L, Grousse A, Sand P, Daniell G, Kowalski JW, Thompson C, Zhou J, Sievert KD. Botulinum toxin type A (BOTOX®) demonstrates dose-dependent efficacy and improvements in quality of life measures in patients with idiopathic overactive bladder. [Podium]. International Urogynecological Association, Annual Meeting, 16-20 June 2009. Como, Italy.

Kowalski JW, Walt JG, Nafees B, Rentz AM, Revicki DA, Brazier JE, Hays RD. Health state utility valuations from the national eye institute visual function questionnaire.  [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 3-7 May 2009; Fort Lauderdale, Florida.

Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Kowalski JW, Zhou J. Botulinum toxin A (BOTOX®) demonstrates dose-dependent improvements in health-related quality-of-life measures in idiopathic overactive bladder. [Poster]. American Urological Association (AUA) Conference, 25-30 April 2009; Chicago, Illinois.

Hollingworth W, Campbell J, Kowalski J, Ravelo A, Girod I, Briggs A, Sullivan S. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition specific quality of life on preference-based outcomes. [Poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Europe, 8-11 Nov 2008, Athens, Greece.

Wijeratne L, Nguyen H, Nordstrom B, Bennett T, Mahab S, Kowalski JW. Diagnosed prevalence & treatment rates of major retinal diseases in the United States. [Poster]. Academy of Managed Care Pharmacy Educational Conference, 16-19 Oct 2008, Kansas City, Missouri.

Curtis L, Fekrat S, Shea A, Hammill B, Kowalski J, Nguyen H, Schulman K. Resource utilization and direct medical costs for elderly patients with incident central retinal vein occlusion (CRVO). [Podium]. American Society of Retina Specialists, 11-15 Oct 2008, Maui, Hawaii.

Curtis L, Fekrat S, Shea A, Hammill B, Kowalski J, Nguyen H, Schulman K. Resource utilization and direct medical costs for elderly patients with incident branch retinal vein occlusion (BRVO). [Poster]. American Society of Retina Specialists, 11-15 Oct 2008, Maui, Hawaii.

Revicki D, Nafees B, Meguro M, Kowalski J, Walt J, Hansen J, Brazier J, Hays R. Item reduction of National Eye Institute Visual Function Questionnaire-25 using Rasch analysis. [Poster]. World Ophthalmology Congress, 28 June – 2 July 2008, Hong Kong, China.

Nafees B, Rentz A, Revicki DA, Meguro M, Kowalski JW, Walt J, Brazier J, Hays RD. Identifying a shortened list of items from the national eye institute visual function questionnaire for a preference-base measure. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO),  27 April – 1 May 2008, Fort Lauderdale, Florida.

Curtis L, Shea A, Hammill B, Kowalski J, Ravelo A, Paul Lee P, Sloan F, Schulman K. Cost of illness associated with diabetic macular edema. [Podium]. Association of Research in Vision and Ophthalmology, 27 April – 1 May 2008, Fort Lauderdale, Florida.

McIntosh R, Rogers S, Cheung N, Lim L, Wang J, Mitchell P, Kowalski J.  Natural history of retinal vein occlusion: Systematic review and meta-analysis. [Poster]. Association of Research in Vision and Ophthalmology, 27 April – 1 May 2008, Fort Lauderdale, Florida.

Hornberger J, Shewade A, Boderne J, Nguyen H, Kowalski JW. A systematic literature review of utilities associated with visual acuity in retinal diseases. [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 27 April – 1 May 2008, Fort Lauderdale, Florida.

Hsieh LJ, Kowalski JW, Ravelo A. Assessment of compliance with overactive bladder oral medications. [Poster].  Academy of Managed Care Pharmacy Educational Conference, 24- 27 Oct 2007, Boston, Massachusetts.

Kowalski JW, Lloyd A, Walt J, Rentz A, Lee JT. Evaluating the benefits of treatments for ophthalmic conditions using utility analysis.  Which metric to use? [Poster]. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), 6-10 May 2007, Fort Lauderdale, Florida.

Carruthers A, Carruthers J, Cox SE, Fagien S, Finn JC, Kowalski JW, Lowe N, Ravelo A, Stone C, Stotland MA, Werschler WP. Patients’ assessment of age-related appearance after botulinum toxin type A treatment of upper facial rhytids:  results across 6 clinical studies. [Poster]. American Academy of Dermatology 65th Annual Meeting, 2-6 February 2007, Washington, DC.

Fagien S, Stone C, Cox SE, Werschler WP, Finn JC, Kowalski JW, Ravelo A. Patient-reported outcomes in subjects receiving botulinum toxin type A treatment for moderate to severe glabellar rhytids:  results from two randomized, double-blind, placebo-controlled studies. [Poster]. American Academy of Dermatology 65th Annual Meeting, 2-6 Feb 2007, Washington, DC.

Glasser D, Kowalski JW, Ravelo A, Weng E, Beddingfield F. Functional and dermatology-specific quality of life benefits with repeated BOTOX® treatment of primary axillary hyperhidrosis over 4 years. [Poster]. American Academy of Dermatology 65th Annual Meeting, 2-6 Feb 2007, Washington, DC.

Kowalski JW, Ravelo A, Weng E, Slaton T. Minimal important difference of the dermatology life quality index in patients with axillary and palmar HH. [Poster]. American Academy of Dermatology 65th Annual Meeting, 2-6 Feb 2007, Washington, DC.

Carruthers A, Carruthers J, Cox SE, Fagien SE, Finn JC, Kowalski JW, Lowe N, Ravelo A, Stotland MA, Werschler WP. Patients’ self-perception of age after botulinum toxin type A treatment of upper facial rhytids: Results across multiple clinical studies.  [Poster]. American Academy of Dermatology 64th Annual Meeting, 3-7 Mar 2006, San Francisco, California.

Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. [Poster]. American Academy of Dermatology 64th Annual Meeting, 3-7 Mar 2006, San Francisco, California.

Glaser DA, Kowalski JW, Ravelo A, Weng E, Beddingfield F. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis. [Poster]. American Academy of Dermatology 64th Annual Meeting, March 3-7, 2006; San Francisco, California.

Kowalski JW, Ravelo A, Bramley T, Jackson J, Lee JT. Economic analysis of tazarotene 0.1% versus adapalene 0.1% and tretinoin microsphere 0.1% for the treatment of mild to moderate facial acne vulgaris. [Poster]. American Academy of Dermatology 64th Annual Meeting, 3-7 Mar 2006, San Francisco, California.

Pariser D, Glaser DA, Ravelo A, Kowalski JW, Lerner D, Lee L. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study. [Poster]. American Academy of Dermatology 64th Annual Meeting, 3-7 Mar 2006, San Francisco, California.

Carruthers A, Carruthers J, Cox SE, Fagien S, Finn JC, Kowalski JW, Lowe N, Ravelo A, Stotland MA, Werschler WP. Patients’ self-perception of age after botulinum toxin type A treatment of upper facial rhytids:  results across multiple clinical studies. [Poster]. American Academy of Dermatology Summer Meeting, 26-30 July  2006, San Diego, California.

Glaser DA, Kowalski JW, Weng EY, Ravelo A, Daggett S, Eadie N.  Effect of repeated botulinum toxin type A treatment on health-related quality of life and functioning in patients with primary axillary hyperhidrosis: results from 2 years of longitudinal data. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Glaser DA, Pariser D, Stolman LP, Kowalski JW, Solish N, Benohanian A, Eadie N, Brin MF, Ravelo A, Weng EY, Reese PR.  Hyperhidrosis disease severity scale: validity and reliability results from 3 studies. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Kowalski JW, Kozma C, Reese PR, Slaton T, Lee J. Initial development of a patient-completed questionnaire to assess outcomes of aesthetic treatment for hyperfunctional facial lines of the upper face. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Kowalski JW, Strutton DR, Ravelo A, Lee JT.  Cost-effectiveness and budget impact of botulinum toxin type A treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Pariser D, Glaser DA, Ravelo A, Kowalski JW, Ill D, Weng EY, Lerner D.  Work productivity impairment in patients with severe primary axillary hyperhidrosis: initial results from the work limitations questionnaire. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Stotland MA, Kowalski JW, Ray BB, Ravelo AL, Dessain AD, Zadorozhna IK. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytids: results from a prospective open-label study. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Kowalski JW, Strutton DR, Ollendorf D.  Diagnosed prevalence and treatment rate of hyperhidrosis:  projections to the 2002-2003 US insured population. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Kowalski JW, Glaser DA, Lowe NJ, Ravelo A.  Quality-of-life and economic impact of primary axillary hyperhidrosis: results from a North American clinical study population. [Poster]. American Academy of Dermatology Summer Meeting, 20-24 July 2005, Chicago, Illinois.

Kowalski JW, Ravelo A, Strausbaugh H.  Effectiveness and patient satisfaction with topical aluminum chloride and endoscopic transthoracic sympathectomy for primary axillary hyperhidrosis: a literature review. [Poster].  American Academy of Dermatology, 63rd Annual Meeting, 18-22 Feb 2005, New Orleans, Louisiana.

Kowalski J, Ravelo A, Saulay M, Fraczek S, Eadie N, Lowe NJ. Patient self-perceptions and satisfaction with botulinum toxin type A treatment for moderate to severe crow’s feet:  results from a placebo-controlled clinical study. [Poster]. American Academy of Dermatology 63rd Annual Meeting, 18-22 Feb 2005, New Orleans, Louisiana.

Hamm H, Naumann MK, Kozma C, Kowalski JW, Kütt S, Teale C.  Primary focal hyperhidrosis: comparison of functional impairment, health-related quality of life, and medical history across a large cohort of patients by focal location and non-hyperhidrotic controls. [Poster]. American Academy of Dermatology, 63rd Annual Meeting, 18-22 Feb 2005, New Orleans, Louisiana

Leonardi CL, Kowalski JW, Walker PS, Ravelo A.  Improving patient satisfaction in patients with moderate to severe psoriasis. [Poster]. American Academy of Dermatology Summer Meeting, July 2004, New York, New York.

Koo JYM, Kowalski JW, Guenther L, Walker PS, Ravelo A. Quality of life effect of oral tazarotene in patients with moderate to severe psoriasis as measured by the 12-Item Psoriasis Quality of Life Questionnaire (PQOL-12).  [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004, Washington, DC.

Kowalski JW, Leyden JJ, Tan JKL, Walker PS, Ravelo A.  Effects of oral tazarotene on health-related quality of life in patients with severe nodulocystic acne: results from a phase 2 dose-ranging study. [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004, Washington, DC.

Spalding JR, Kowalski JW, Lee JT, Glaser DA. Effect of pharmacologic treatment on dermatologic-specific quality of life:  a comparison of botulinum toxin type A for primary focal hyperhidrosis to medical treatments for other dermatological diseases. [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004. Washington, DC.

Kowalski JW, Glaser DA, Lowe NJ, Ravelo A. Quality of life effect of botulinum toxin type A on patients with primary axillary hyperhidrosis: results from a North American clinical study population. [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004, Washington, DC.

Lee JT, Kowalski JW, Ravelo A.  Cost-effectiveness of tazarotene 0.1% cream versus adapalene 0.1% cream for the treatment of facial acne vulgaris. [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004, Washington, DC.

Kowalski JW, Eadie N, Daggett S, Lai PY, Mordaunt J, Strutton DR, Glaser DA.  Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS). [Poster]. American Academy of Dermatology, 62nd Annual Meeting, 6-11 Feb 2004, Washington, DC.

Naumann M, Hamm H, Spalding JR, Kowalski JW, Lee J.  Comparing the quality of life effects of primary focal hyperhidrosis to other dermatological conditions as assessed by the Dermatology Life Quality Index (DLQI).  [Poster]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 18-23 May 2003, Arlington, Virginia.

Koo JYM, Kozma C, Menter A, Lebwohl M, Abramovits W, Lorenzo C, Slaton TL, Wojcik A, Brady CJ, Kowalski JW.  Development of a disease specific quality of life questionnaire:  the 12-item Psoriasis Quality of Life Questionnaire (PQOL-12). [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Kozma C, Slaton TL, Walker PS, Kowalski JW, Menter A, Koo JYM, Lebwohl M, Hornberger J.  Predicting psoriasis area and severity (PASI) scores with alternative clinical measures. [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Naumann MK, Lowe NJ, Kumar CR, Hamm H, Kowalski JW.  Long-term quality of life and clinical effect of botulinum toxin type A for bilateral primary axillary hyperhidrosis: final results of a 16-month prospective study in Europe. [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Naumann MK, Hamm H, Kowalski JW.  Economic and quality-of-life impact of primary axillary hyperhidrosis:  results from a European clinical study population. [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Strutton DR, Kowalski JW, Glaser DA, Stang PE.  U.S. prevalence of hyperhidrosis: results from a national survey.  [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Strutton DR, Kowalski JW, Glaser DA, Stang PE.  Impact of hyperhidrosis on daily activities for individuals in the U.S. with axillary hyperhidrosis: results from a national survey. [Poster]. American Academy of Dermatology, 61st Annual Meeting, 21-26 Mar 2003, San Francisco, California.

Koo J, Menter A, Lebwohl M, Kozma C, Slaton T, Wojcik A, Kowalski JW.  The relationship between quality of life and disease severity: results from a large cohort of mild, moderate, and severe psoriasis patients. [Poster]. Psoriasis: from Gene to Clinic, Third International Congress. The Royal College of Physicians. 21-23 Nov 2002, London, United Kingdom.

Teale C, Hamm H, Naumann M, Roberts G, Kowalski JW. Development, validity, and reliability of the Hyperhidrosis Impact Questionnaire (HHIQ). [Poster].  International Society for Quality of Life (ISOQOL) Research Conference, 30 Oct – 2 Nov 2002, Orlando, Florida.

Kowalski JW, Cox SE, Finn C, Mackowiak J.  Development, validity, and reliability of the facial lines treatment satisfaction (FTS) questionnaire. [Poster]. International Society for Quality of Life Research Conference (ISOQOL) Conference, 30 Oct – 2 Nov 2002, Orlando, Florida.

Kowalski JW, Sengelmann RD, Waldorf H, Fagien S, Fields N, Mackowiak J.  Development, validity, and reliability of the facial lines self-confidence and perceptions (FSP) questionnaire. [Poster]. International Society for Quality of Life Research Conference (ISOQOL) Conference, 30 Oct – 2 Nov 2002, Orlando, Florida.

Walt JG, Cross WD, Kozma C, Kowalski JW.  Cyclosporine therapy for the treatment of tear film insufficiency:  results from a one-year follow-up study. [Poster]. Association for Research in Vision and Ophthalmology, 29 April – 4 May 2001, Fort Lauderdale, Florida.

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies